Edition:
United Kingdom

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

0.76USD
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
$0.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
181,233
52-wk High
$4.24
52-wk Low
$0.75

Latest Key Developments (Source: Significant Developments)

Advaxis Reports Fiscal 2018 Q3 Loss Per Share Of $0.27
Monday, 10 Sep 2018 

Sept 10 (Reuters) - Advaxis Inc ::ADVAXIS REPORTS FISCAL 2018 THIRD QUARTER BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.27.QTRLY REVENUE $1.2 MILLION VERSUS $3.1 MILLION.  Full Article

Advaxis Inc Files For Mixed Shelf Of Up To $250 Million
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Advaxis Inc ::ADVAXIS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION .  Full Article

Advaxis Announces FDA Allowance Of IND Application For ADXS-Hot Drug Candidate
Monday, 30 Jul 2018 

July 30 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES FDA ALLOWANCE OF IND APPLICATION FOR ADXS-HOT DRUG CANDIDATE FOR NON-SMALL CELL LUNG CANCER.ADVAXIS INC - AFFIRMS PLANS TO SUBMIT A TOTAL OF FOUR IND FOR DRUG CANDIDATES FROM ITS ADXS-HOT PROGRAM BY Q4 OF 2019.ADVAXIS - PLANS TO INITIATE PHASE 1/2 CLINICAL TRIAL THAT WILL SEEK TO ESTABLISH SAFETY, TOLERABILITY AND EFFECTIVENESS OF ADXS-503.ADVAXIS INC - ANTICIPATES FIRST PATIENT IN PHASE 1/2 TRIAL FOR THIS NSCLC DRUG CANDIDATE WILL BE DOSED BY END OF 2018.  Full Article

Advaxis Says FDA Lifts Clinical Hold On Phase 1/2 Combination Study Of Axalimogene Filolisbac
Friday, 13 Jul 2018 

July 13 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES FDA LIFTS CLINICAL HOLD ON PHASE 1/2 COMBINATION STUDY OF AXALIMOGENE FILOLISBAC WITH DURVALUMAB.ADVAXIS INC - ENROLLMENT AND DOSING IN ALL OTHER ADVAXIS AND DURVALUMAB CLINICAL PROGRAMS WERE NOT AFFECTED BY CLINICAL HOLD.  Full Article

Advaxis Appoints Molly Henderson As Chief Financial Officer
Wednesday, 6 Jun 2018 

June 6 (Reuters) - Advaxis Inc ::ADVAXIS APPOINTS MOLLY HENDERSON AS CHIEF FINANCIAL OFFICER.ADVAXIS INC - HENDERSON JOINS ADVAXIS FROM CEDAR CLIFF, LLC.  Full Article

Advaxis Announces Executive Leadership Changes
Monday, 23 Apr 2018 

April 23 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES EXECUTIVE LEADERSHIP CHANGES.ADVAXIS INC - KENNETH BERLIN HAS BEEN APPOINTED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.ADVAXIS INC - INTERIM CEO ANTHONY LOMBARDO WILL REMAIN WITH ADVAXIS FOR A PERIOD OF TIME.  Full Article

Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Advaxis Inc ::ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC.ARATANA THERAPEUTICS-U.S. DEPARTMENT OF AGRICULTURE CENTER FOR VETERINARY BIOLOGICS GRANTED CONDITIONAL LICENSE​ FOR CANINE OSTEOSARCOMA VACCINE,AT-014.  Full Article

BRIEF-Advaxis Announces Executive Leadership Changes

* ADVAXIS INC - KENNETH BERLIN HAS BEEN APPOINTED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER